Robert I. Fox

16.3k total citations · 4 hit papers
137 papers, 12.6k citations indexed

About

Robert I. Fox is a scholar working on Physiology, Immunology and Rheumatology. According to data from OpenAlex, Robert I. Fox has authored 137 papers receiving a total of 12.6k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Physiology, 39 papers in Immunology and 36 papers in Rheumatology. Recurrent topics in Robert I. Fox's work include Salivary Gland Disorders and Functions (63 papers), Systemic Lupus Erythematosus Research (22 papers) and Diabetes and associated disorders (19 papers). Robert I. Fox is often cited by papers focused on Salivary Gland Disorders and Functions (63 papers), Systemic Lupus Erythematosus Research (22 papers) and Diabetes and associated disorders (19 papers). Robert I. Fox collaborates with scholars based in United States, Japan and Germany. Robert I. Fox's co-authors include Michael E. Stern, Paul E. Michelśon, Roy Fleischmann, M. Lange, Daniel Burge, Arthur D. Bankhurst, Joel M. Kremer, Michael E. Weinblatt, Ken J. Bulpitt and Hoil Kang and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Robert I. Fox

136 papers receiving 12.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate

1999 1.6k citations Michael E. Weinblatt, Joel M. Kremer et al. New England Journal of Medicine profile →
Sjögren's syndrome

2005 1.3k citations Robert I. Fox The Lancet profile →
The Pathology of Dry Eye

1998 661 citations Michael E. Stern, Robert I. Fox et al. profile →
Sjögren's syndrome. Proposed criteria for classification

1986 550 citations Robert I. Fox et al. Arthritis & Rheumatism profile →

Peers

Countries citing papers authored by Robert I. Fox

Since Specialization

Citations

This map shows the geographic impact of Robert I. Fox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert I. Fox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert I. Fox more than expected).

Fields of papers citing papers by Robert I. Fox

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert I. Fox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert I. Fox. The network helps show where Robert I. Fox may publish in the future.

Co-authorship network of co-authors of Robert I. Fox

This figure shows the co-authorship network connecting the top 25 collaborators of Robert I. Fox. A scholar is included among the top collaborators of Robert I. Fox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert I. Fox. Robert I. Fox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52‐Week Results From a Randomized, Placebo‐Controlled, Phase 2b Dose‐Ranging Study 2024 ·Arthritis & Rheumatology ·Thomas Dörner, Simon Bowman, Robert I. Fox, Xavier Mariette, Athena Papas, Thomas Grader‐Beck, Benjamin A. Fisher, Filipe Barcelos, Salvatore De Vita, Hendrik Schulze‐Koops, Robert J. Moots, G. Junge, (unknown), Monika Sopala, Alexandre Avraméas, Wen‐Lin Luo, Wolfgang Hueber	3
2	Immunologic basis for development of keratoconjunctivitis sicca in systemic autoimmune diseases: Role of innate immune sensors 2024 ·The Ocular Surface ·Michael E. Stern, Argyrios N. Theofilopoulos, Philipp Steven, Jérry Y. Niederkorn, Robert I. Fox, Margarita Calonge, Christof Scheid, Stephen C. Pflugfelder	3
3	Rethinking Sjögren Beyond Inflammation: Considering the Role of Nerves in Driving Disease Manifestations 2024 ·Eye & Contact Lens Science & Clinical Practice ·(unknown), (unknown), Robert I. Fox, Anat Galor	3
4	Treatment of Sjögren’s syndrome: current therapy and future directions 2019 ·Lara D. Veeken ·Robert I. Fox, (unknown), Jacques Éric Gottenberg, Thomas Dörner	69
5	Sjögren Syndrome 2016 ·Rheumatic Disease Clinics of North America ·Robert I. Fox, (unknown)	15
6	Sjögren's syndrome breakdown → 2005 ·The Lancet ·Robert I. Fox	1308
7	Use of Cevimeline, a Muscarinic Ml and M3 Agonist, in the Treatment of Sjögren’s Syndrome 2002 ·Advances in experimental medicine and biology ·Robert I. Fox	16
8	Sjogren’s syndrome: 2000 ·Clinics in Dermatology ·Robert I. Fox, Paul E. Michelśon, Carlos A. Casiano, Joichiro Hayashi, Michael E. Stern	339
9	A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate breakdown → 1999 ·New England Journal of Medicine ·Michael E. Weinblatt, Joel M. Kremer, Arthur D. Bankhurst, Ken J. Bulpitt, Roy Fleischmann, Robert I. Fox, (unknown), M. Lange, Daniel Burge	1612
10	Mechanism of Action for Leflunomide in Rheumatoid Arthritis 1999 ·Clinical Immunology ·Robert I. Fox, Matthias Herrmann, Costakis Frangou, Geoffrey M. Wahl, Randall E. Morris, Vibeke Strand, Bernhard J. Kirschbaum	312
11	Pathogenesis and treatment of Sj??gren??s syndrome 1997 ·Current Opinion in Rheumatology ·Robert I. Fox, Toshiaki Maruyama	55
12	Clinical features, pathogenesis, and treatment of Sj??gren??s syndrome 1996 ·Current Opinion in Rheumatology ·Robert I. Fox	58
13	Systemic Diseases Associated with Dry Eye 1994 ·International Ophthalmology Clinics ·Robert I. Fox	15
14	Lymphoproliferative disease in scid mice reconstituted with human Sjögren's syndrome lymphocytes 1993 ·Journal of Clinical Laboratory Analysis ·Robert I. Fox, Pavel Pisa, Eva K. Pisa, (unknown)	6
15	Reactivation of Epstein-Barr virus in Sjögren's syndrome 1991 ·Springer Seminars in Immunopathology ·Robert I. Fox, Mario Luppi, Hoil Kang, Pavel Pisa	46
16	Summary of the third international sjögren's syndrome symposium 1991 ·Arthritis & Rheumatism ·Robert I. Fox	2
17	Dissociation of immune responses to the ss‐a (ro) 52‐kd and 60‐kd polypeptides in systemic lupus erythematosus and sjögren's syndrome 1990 ·Arthritis & Rheumatism ·Eldad Ben‐Chetrit, Robert I. Fox, Eng M. Tan	126
18	Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjogren's syndrome. 1989 ·The Journal of Experimental Medicine ·Ichiro Saito, B Servenius, T Compton, Robert I. Fox	346
19	Idiotypic and genetic studies of human rheumatoid factors 1987 ·Arthritis & Rheumatism ·Dennis A. Carson, Pojen P. Chen, Thomas J. Kipps, Victor Radoux, Frank R. Jirik, R D Goldfien, Robert I. Fox, Gregg J. Silverman, Sherman Fong	32
20	Characterization of a Crossreactive Idiotype in Sjögren’s Syndrome 1986 ·Scandinavian Journal of Rheumatology ·Robert I. Fox, Dennis A. Carson, (unknown), Sherman Fong	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact